Aurealis Therapeutics, a Swiss-Finnish synthetic biology and China-based Xbiome, an AI-based microbiome drug development company, on Friday announced that they have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational diabetic foot ulcer (DFU), other chronic wounds, and inflammatory disease therapy AUP-16 in Greater China.
Under the terms of the license and collaboration agreement, Xbiome acquires exclusive development and commercial rights for all human use to Aurealis clinical stage DFU drug candidate AUP-16 in Mainland China, Hong Kong, Macao, and Taiwan.
Xbiome, which last month complete a $100 million Series B financing, will be responsible for all clinical and other development, regulatory submissions, and commercialization of the licensed products in the licensed territory. Aurealis retains full rights to AUP-16 outside of the specified territory and will continue to lead the global development of the drug candidate. The companies will collaborate on the joint development for DFU and potentially on other selected indications.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze